Fundraising FoxBiotech Startups
11,114 companies tagged Biotech, with their investors and founders.
0 investors
0 investors
Persevere Therapeutics is a clinical-stage oncology company developing misetionamide, a small molecule asset with a novel dual-target mechanism that inhibits cancer cell energy metabolism and proliferation. The company is advancing misetionamide through clinical trials for platinum-resistant ovarian cancer and other tumor types including pancreatic, melanoma, and colorectal cancers.
0 investors
Personalized Stem Cells develops regenerative medicine treatments using stem cells derived from adipose tissue, serving patients seeking cell therapies for conditions like osteoarthritis and other ailments in both humans and animals. The company operates from San Diego under FDA guidelines and offers stem cell banking and treatment services through its StemReady and StemPreserve programs.
0 investors
0 investors
Petros Pharmaceuticals is a bio-pharmaceutical company working to convert prescription drugs into over-the-counter self-care treatments, allowing consumers access without a physician visit or prescription. It operates in the emerging self-care pharmaceutical market.
0 investors
PetVivo is a veterinary biotech and biomedical device company that adapts human biotech and medical technology into products for the veterinary market. Its lead product, Spryng with OsteoCushion Technology, uses proprietary protein-based biomaterials to manage joint pain, lameness, and osteoarthritis in companion animals such as dogs and horses.
0 investors
0 investors
0 investors
0 investors
PharmaCyte is a biotechnology company developing Cell-in-a-Box, a live-cell encapsulation technology, to create cellular therapies for cancer, diabetes, and malignant ascites. The company encapsulates genetically engineered human cells to deliver localized drug activation or insulin production.
0 investors
0 investors
Pharmather develops personalized therapeutic treatments, focusing on ketamine and cepharanthine-based therapies for mental health and other conditions.
0 investors
Pharmazz is a biopharmaceutical company developing and commercializing therapeutics for critical care and acute medicine, focused on Endothelin-B receptor agonists and resuscitative agents for conditions such as hypovolemic shock, ischemic stroke, and septic shock. Its lead products include Centhaquine (Lyfaquin) for hypovolemic shock and Tyvalzi for cerebral stroke, with operations in the U.S. and India.
0 investors
0 investors
PhAST develops AI and machine learning imaging technology for infectious disease diagnostics, using single-cell imaging and a cloud-based platform to address antibiotic resistance. Its platform provides clinical decision support for doctors, workflow tools for hospitals, and drug development support for pharmaceutical companies.
0 investors
0 investors
0 investors
PhenoVista provides contract research services focused on phenotypic and high-content imaging studies, using quantitative fluorescence microscopy and cell-based disease models to support R&D and drug discovery decisions. It serves life science and biotech researchers.
0 investors
Phitherapeutics (brand Phyla) develops patented bacteriophage-based skincare that targets acne-causing C. acnes bacteria while preserving the skin barrier and microbiome. Its phage treatment is marketed to consumers and recommended by licensed dermatologists and skin professionals.
0 investors
Phigenix develops personalized medicine for cancer, including companion diagnostics and targeted therapies for prostate and breast cancer patients. Its work centers on early detection and targeted inhibition of PAX2 and EN2 oncogenes and a cancer vaccine using Human Beta Defensin-1 (DEFB1) mRNA to direct the immune system against cancer cells.
0 investors
Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing INTASYL, a proprietary self-delivering siRNA gene silencing technology that makes immune cells more effective at killing cancer cells. Its immuno-oncology pipeline targets cutaneous squamous cell carcinoma (cSCC) and melanoma.
0 investors
pHLIP Inc. develops a peptide-based targeted delivery platform (pHLIP, pH-Low Insertion Peptide) that selectively delivers therapeutic and imaging agents to acidic cells in diseased tissues. The technology targets cancer, inflammation, and other acidic tissue diseases by marking, reprogramming, or killing acidic cells.
0 investors
0 investors